Exploring the Long-Term Psychosocial Impacts of Stage IV Melanoma in Survivors
Source: Dermatology Times, May 2025
Stage IV melanoma survivors face persistent adverse effects and distress, highlighting the need for targeted psychological support and care.
A recent trial has evaluated persistent psychosocial effects and long-term toxicity in stage IV melanoma survivors.1 This study is the first of its kind to evaluate the long-term psychological impacts of late-stage melanoma.
Stage IV melanoma survival rates have increased from 5% to 30% in the last 15 years. Patients who received immune checkpoint inhibition and targeted therapy have an even higher survival rate of 50%.2